Previous 10 | Next 10 |
home / stock / mpsyf / mpsyf news
Unofficial sources said Joincare would seek to raise around $300 to $400 million. META Pharma of Shenzhen raised $15 million in Seed and Pre-A rounds to fund its immunometabolism-based small-molecule drug discovery operations. CANbridge, a Beijing-Cambridge MA rare disease/rare on...
NAT is bullish on spot tanker rates because of Russia's involvement in armed conflict with Ukraine, and most of its tankers are in the spot market. However, Suezmax tanker rates have dropped since their spike. Oil demand fundamentals have softened and high oil prices are dampening...
MorphoSys AG (MOR) Q1 2022 Earnings Conference Call May 05, 2022, 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - CEO Sung Lee - CFO Malte Peters - Chief Research & Development Officer Joe Horvat - U.S. General Manager Conference Call Participants James Quigley - ...
MorphoSys AG (MOR) Q4 2021 Results Conference Call March 17, 2022 08:00 AM ET Company Participants Julia Neugebauer - IR Jean-Paul Kress - Chief Executive Officer Sung Lee - Chief Financial Officer Malte Peters - Chief Research & Development Officer Joe Horvat - U.S. General Manager Confe...
This article focuses on the major influences towards a biotech company's share price, rather than their value or opportunity. These catalysts will be important to consider when timing your entry and exit points. This article will be the last that focuses on evaluating individual h...
MorphoSys AG (MOR) Q3 2021 Results Earnings Conference Call November 11, 2021, 08:00 AM ET Company Participants Julia Neugebauer - Senior Director, Investor Relations Jean-Paul Kress - Chief Executive Officer Malte Peters - Chief Research and Development Officer Sung Lee - Chief Financial Off...
The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q3 earnings call. For further details see: MorphoSys AG 2021 Q3 - Results - Earnings Call Presentation
The following slide deck was published by MorphoSys AG in conjunction with their 2021 Q2 earnings call. For further details see: MorphoSys AG 2021 Q2 - Results - Earnings Call Presentation
MorphoSys AG (MOR) Q2 2021 Earnings Conference Call July 29, 2021 08:00 ET Company Participants Julia Neugebauer - Senior Director, Investor Relations Jean-Paul Kress - Chief Executive Officer Sung Lee - Chief Financial Officer Roland Wandeler - Chief Operating Officer Malte Peters - Chief Re...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Recent Strategy outperformance has been broad-based, led ...
News, Short Squeeze, Breakout and More Instantly...
Morphosys Ag Ord Company Name:
MPSYF Stock Symbol:
OTCMKTS Market:
PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 20, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) announces that Novartis BidCo Germany AG informed the MorphoSys AG Management Board of its intention to merge MorphoSys AG as transferring company into Novartis BidCo Germany AG. Novartis BidCo Germany ...
Additional ASCO 2024 poster presentation will include new findings from the Phase 2 study of tulmimetostat PLANEGG and MUNICH, GERMANY / ACCESSWIRE / April 24, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that new efficacy and safety data from the Phase 3 MANIFEST-2 trial of pel...
Novartis offers € 68.00 per share in cash, representing a total equity value of € 2.7 billion Shareholders benefit from attractive premium of 94% and 142% on the volume-weighted average price during the last month and three months before January 25, 2024, respectively Acce...